Tramadol: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Expand stub to full MedTemplate parameter set |
Safety wave: 2017 FDA boxed warning + pediatric/breastfeeding contraindications (FDA DSC April 20 2017); M1 affinity framing + CPIC 2021 cite |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Tramadol | ||
| brand | | brand = Ultram (IR), Ultram ER, ConZip ER | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Opioid analgesics|Opioid analgesic (atypical, weak μ-agonist with serotonin/norepinephrine reuptake inhibition)]], [[:Category:Schedule IV controlled substances|Schedule IV controlled substance]], [[:Category:Analgesics|Analgesic]] | ||
| | | uses = <vote slug="moderate-severe-pain-use">Moderate to moderately severe pain (FDA)</vote>, <vote slug="chronic-pain-tramadol-use">Chronic pain in opioid-sparing regimens (off-label)</vote>, <vote slug="restless-legs-syndrome-use">Restless legs syndrome (off-label, second-line)</vote>, <vote slug="neuropathic-pain-broad-use">Neuropathic pain (off-label)</vote> | ||
| starting_dose = IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days | |||
| starting_dose | | preparations = IR tablets 50 mg; ER tablets 100, 200, 300 mg (Ultram ER, ConZip); oral solution 5 mg/mL; combination products with acetaminophen (Ultracet) | ||
| preparations | | fda_max = 400 mg/day (IR, adult); 300 mg/day (ER); 300 mg/day in elderly >75 years | ||
| | | pill_id = | ||
| | | routes = Oral | ||
| onset = 30-60 minutes (IR) | |||
| | | duration = 4-6 hours (IR); 24 hours (ER) | ||
| | | halflife = Tramadol 6-7 hours; M1 active metabolite 7-9 hours<ref name="ultram-label">FDA Prescribing Information, Ultram (tramadol hydrochloride), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020281s048lbl.pdf</ref> | ||
| | | bioavailability = ~75% (IR, rises with multi-dose administration due to saturable first-pass)<ref name="ultram-label" /> | ||
| | | pregnancy = Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.{{citation needed}} | ||
| legal = [[USLegal:Schedule IV|Schedule IV controlled substance]] in US (federally scheduled 2014); some states schedule higher<ref name="ultram-label" /> | |||
| | | mechanism = <vote slug="tramadol-mech-claim">Tramadol acts partly as a prodrug for opioid effect: CYP2D6 converts it to O-desmethyltramadol (M1), which binds the mu-opioid receptor with substantially higher affinity than the parent compound (reported on the order of 200-fold, with estimates varying by assay), so M1 is the dominant opioid-active moiety while parent tramadol contributes serotonin and norepinephrine reuptake inhibition.<ref>Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.</ref> Pharmacogenomic guidance on CYP2D6 metabolizer status for opioid selection is provided by the Clinical Pharmacogenetics Implementation Consortium.<ref>Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896.</ref></vote> CYP2D6 ultra-rapid metabolizers produce dangerously high M1 levels with risk of fatal respiratory depression, particularly in children; CYP2D6 poor metabolizers get reduced opioid analgesic benefit and rely on the serotonin/norepinephrine reuptake component. '''Serotonin syndrome''' risk with SSRIs, SNRIs, MAOIs, and other serotonergic agents. '''Seizure''' risk is dose-dependent and elevated in patients with epilepsy, head trauma, or concurrent serotonergic medicines. | ||
| monitoring = '''Boxed warning:''' tramadol carries an FDA boxed warning for life-threatening respiratory depression arising from ultra-rapid CYP2D6 metabolism to the active metabolite O-desmethyltramadol (M1), alongside the opioid-class warnings for addiction, abuse, and misuse and for fatal interaction with benzodiazepines and other CNS depressants.<ref>U.S. Food and Drug Administration. Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. April 20, 2017.</ref> Tramadol is contraindicated for any use in children younger than 12 years, and contraindicated in children younger than 18 years to treat pain after tonsillectomy and/or adenoidectomy; use in adolescents 12 to 18 years is not recommended when they have obesity, obstructive sleep apnea, or severe lung disease.<ref>FDA Drug Safety Communication, April 20, 2017 (as above); tramadol prescribing information, Boxed Warning.</ref> Use is not recommended in breastfeeding women because M1 passes into breast milk and can cause sedation and life-threatening respiratory depression in the infant, especially of an ultra-rapid metabolizer.<ref>American College of Obstetricians and Gynecologists. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017;130(2):e81-e94.</ref> | |||
| | |||
| | |||
| | |||
| | |||
| monitoring | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Opioid analgesics]] | |||
[[Category:Schedule IV controlled substances]] | |||
[[Category:Analgesics]] | [[Category:Analgesics]] | ||